Argenx : Excellent T3 2024 au-dessus des attentes. OC relevé à 580 €
>Au-dessus des attentes au niveau des ventes et de l’EBIT - Les ventes T3 progressent de 74% y-o-y et de 34% q-o-q pour atteindre 573 M$ (USA à 492 M$, Japon 24 M$, EMEA 46 M$ et 11 M$ de fourniture en Chine), reflétant à la fois la forte demande des produits Vyvgart et Vyvgart Hytrulo ainsi que l’excellente exécution commerciale. Ce trimestre intègre pour la première fois les ventes dans CIDP. La société ne communique pas sur le split par indication mais indique qu...Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.